Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23887762 | 0.88 | DYRK1A (0.40) | PDE2ATLR8IRAK4PIK3CDPIK3CA | |
| SCHEMBL25544956 | 0.87 | TLR9 (0.35) | PDE2ATLR9TLR8TLR7IRAK4 | |
| SCHEMBL25544311 | 0.83 | GRM2 (0.41) | PDE2A | |
| SCHEMBL25544957 | 0.81 | PIK3CD (0.38) | PDE2ATLR9TLR8TLR7IRAK4 | |
| SCHEMBL28974868 | 0.77 | PIK3CD (0.36) | PDE2AIRAK4IRAK1PIK3CDPIK3CA | |
| SCHEMBL23887857 | 0.76 | DYRK1A (0.40) | TLR9TLR8TLR7PIK3CDPIK3CA | |
| SCHEMBL25544952 | 0.75 | PIK3CA (0.40) | PIK3CDPIK3CA | |
| SCHEMBL25544713 | 0.75 | PDE2A (0.37) | PDE2ATLR9TLR8TLR7IRAK4 | |
| SCHEMBL23895975 | 0.73 | PIK3CA (0.40) | PDE2ATLR9TLR8TLR7IRAK4 | |
| SCHEMBL23895721 | 0.73 | TOP1 (0.37) | PDE2ATLR9TLR8TLR7PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | PDE2A 1868/4885TLR9 4766/4885TLR8 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.